Who we are
The Quebec Cancer Consortium for Novel Therapeutics and Biomarkers (QCC) is a collaborative network of four hospitals, with their respective research centres, and two university-based cancer research centres. Its goals are to standardize and harmonize practices in clinical and translational research, to improve cancer treatment by accelerating advances in precision medicine and immuno-oncology, and to engage with cancer patients to develop educational material and raise awareness of clinical trials of precision medicine and immunotherapies.
- The Cedars Cancer Centre at McGill University Health Centre (MUHC) and the Research Institute of the MUHC
- the Jewish General Hospital (JGH) and the Segal Cancer Centre at the JGH
- the Centre hospitalier de l’Université de Montréal (CHUM) and the Research Centre of CHUM
- the Hôpital Maisonneuve-Rosemont (HMR) and the Centre de recherche de l’HMR
- the Rosalind and Morris Goodman Cancer Institute at McGill University and McGill Genome Center
What we do
The QCC is accelerating research on molecular diagnostics and therapeutics for cancer and putting patients’ experiences and needs front and centre.
QCC members are collaborating to advance cancer research and save lives by:
- Developing infrastructure to fuel the discovery and development of new precision cancer therapies and diagnostic tests to match patients with the best possible treatments.
- Translating discoveries from the laboratory to the clinic.
- Educating patients on the essential role of clinical trials in developing new treatments.
- Empowering patients to participate in ongoing and future precision oncology and immunotherapy clinical trials.
What we stand for
We are committed to promoting:
- Scientific Excellence through fostering innovative clinical and translational research based on principles of integrity and ethical practices.
- Multidisciplinary Collaboration across institutions through sharing data and resources, integrating technological platforms and standardizing practices and protocols.
- Patient engagement through partnering with communities to develop inclusive scientific priorities, clinical trials, and research projects.